Table 3. In Vitro Cytotoxic Activity of Newly Synthesized N-Acyl Hydrazone Derivatives^a.

IC50 (μM)
entry	comp. no	MCF-7	PC-3	ME-16C
1	7a	25.41 ± 0.82	57.33 ± 0.92	545.32 ± 0.75
2	7b	10.27 ± 0.63	15.00 ± 0.40	158.37 ± 1.90
3	7c	9.25 ± 0.54	12.57 ± 0.67	227.65 ± 1.76
4	7d	7.52 ± 0.32	10.19 ± 0.52	250.43 ± 1.88
5	7e	12.54 ± 0.84	10.81 ± 0.71	672.18 ± 2.69
6	8a	10.98 ± 1.21	26.57 ± 0.92	471.76 ± 2.98
7	8b	50.75 ± 0.63	51.95 ± 0.88	ND
8	8c	471.53 ± 0.57	510.13 ± 1.10	480.53 ± 2.05
9	8d	510.19 ± 2.88	454.71 ± 2.31	ND
10	8e	490.65 ± 3.49	500.52 ± 2.83	ND
11	9a	120.25 ± 1.87	ND	ND
12	9b	210.00 ± 3.14	275.82 ± 5.9	ND
13	9c	95.02 ± 0.76	106.32 ± 3.7	ND
14	9d	115.95 ± 2.7	152.14 ± 0.75	ND
15	9e	100.08 ± 1.39	125.46 ± 1.1	ND
16	doxorubicin	0.83 ± 0.07	0.75 ± 0.04	0.80 ± 0.09

^aIC₅₀: The concentration that inhibits 50% of cell proliferation; ND: Not determined; ± values represent the standard deviation of the mean.